Andres Bustamante-Arias

Dr. Andres Bustamante-Arias

Tecnologico de Monterrey, Monterrey, Nuevo León, Mexico

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2020 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
RRRaul E. Ruiz-Lozano
Raul E. Ruiz-Lozano
JHJulio C. Hernández‐Camarena
Julio C. Hernández‐Camarena
LGLucas A. Garza‐Garza
Lucas A. Garza‐Garza
ABAndres Bustamante-Arias
Andres Bustamante-Arias
MCMaria F. Colorado‐Zavala
Maria F. Colorado‐Zavala
JGJesus Alberto Cardenas-de la Garza
Jesus Alberto Cardenas-de la Garza

1 September 2021 in Survey of Ophthalmology
Verified
Journal Article
Closed access
ABAndres Bustamante-Arias
Andres Bustamante-Arias
RRRaul E. Ruiz-Lozano
Raul E. Ruiz-Lozano
JAJ. Carlos Alvarez-Guzman
J. Carlos Alvarez-Guzman
SGSara Gonzalez-Godinez
Sara Gonzalez-Godinez
ARAlejandro Rodriguez-Garcia
Alejandro Rodriguez-Garcia

7 August 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
DNDalia Ng
Dalia Ng
JAJuan Carlos Altamirano
Juan Carlos Altamirano
ARAlejandro Gonzalez-de la Rosa
Alejandro Gonzalez-de la Rosa
JNJOSE NAVARRO
JOSE NAVARRO
JVJorge E. Valdez-Garcia
Jorge E. Valdez-Garcia
ASArturo Santos
Arturo Santos
Due to their antioxidant, anti-inflammatory, neuroprotective, and anti-angiogenic effects, polyphenols are first-rate candidates to prevent or treat chronic diseases in which oxidative stress-induced inflammation plays a role in disease pathogenesis. Dry eye disease (DED) is a common pathology, on which novel phenolic compound formulations have been tested as an adjuvant therapeutic approach. However, polyphenols are characterized by limited stability and solubility, insolubility in water, very rapid metabolism, and a very short half-life. Thus, they show poor bioavailability. To overcome these limitations and improve their stability and bioavailability, we evaluated the safety and efficacy of an oral formulation containing among other compounds, polyphenols and omega-3 fatty acids, with the addition of a surfactant in patients with DED. Subjects were randomly assigned to one of four study groups including the study formulation (A), placebo (P), the study formulation + eye lubricant (A + L), and placebo + eye lubricant (P + L). Patients from the A and P groups were instructed to take two capsules every 24 h, while patients in the L groups also added one drop of lubricant twice a day for 12 weeks as well. Regarding safety, non-ocular abnormalities were observed during study formulation therapy. Liver function tests did not show any statistically significant difference (baseline vs. week 4). Concerning efficacy, there was a statistically significant difference between baseline, month 1, and month 3 in the OSDI (Ocular Surface Disease Index) test results in both treatment groups (group A and group A + L). Furthermore, both groups showed statistically significant differences between baseline and month 3 regarding the non-invasive film tear breakup time (NIF-BUT) score and a positive trend related to Shirmer’s test at month 3. The non-invasive average breakup time (NIAvg-BUT) score showed a statistically significant difference at month 3 when compared with baseline in the A + L group. The P + L group showed a statistically significant difference in terms of the OSDI questionary between baseline and month 3. Regarding the lissamine green staining, the A + L group showed a statistical difference between baseline and month 3 (p = 0.0367). The placebo + lubricant group did not show statistically significant differences. Finally, the placebo group did not show any data with statistically significant differences. Consequently, this polyphenol formulation as a primary treatment outperformed the placebo alone, and the polyphenol oral formulation used as an adjuvant to artificial tears was superior to the combination of the placebo and the artificial tears. Thus, our data strongly suggest that this polyphenol oral formulation improves visual strain symptoms and tear film status in patients with mild to moderate DED.

Verified
Journal Article
Open access
PDF file
Sandra Carolina Durán-CristianoSandra Carolina Durán-Cristiano
Sandra Carolina Durán-Cristiano
ABAndres Bustamante-Arias
Andres Bustamante-Arias
GFGeysson Javier Fernandez
Geysson Javier Fernandez
Alba Martín-GilAlba Martín-Gil
Alba Martín-Gil
juan gonzalo carracedo rodriguezjuan gonzalo carracedo rodriguez
juan gonzalo carracedo rodriguez
Keratoconus (KC) is a progressive ocular disorder marked by structural and functional alterations of the cornea, leading to significant visual impairment. Recent studies indicate that these corneal changes are linked to molecular and cellular mechanisms that disrupt and degrade the extracellular matrix. This degradation is influenced by proteinases that contribute to a loss of homeostasis and an imbalance in the antioxidant/oxidative state within the cornea, fostering oxidative stress, inflammation, and apoptosis. Although these biological processes have been identified primarily through molecular biology research, omics technologies have significantly advanced our understanding of the physiological and pathological phenomena associated with KC. Omics studies encompassing genomics, transcriptomics, proteomics, epigenomics, and metabolomics, have emerged as critical tools in elucidating the complex biological landscape of various diseases, including ocular conditions. The integrative application of these studies has demonstrated their potential in personalizing medicine across diverse fields such as oncology, neurology, and ophthalmology. This review aims to describe findings from omics research applied to keratoconus, highlighting the genomic, transcriptomic, proteomic, epigenomic, and metabolomic aspects derived from ocular and other biological samples. Notably, the molecular insights gained from these studies hold promise for identifying biomarkers of keratoconus, which could enhance diagnostic accuracy and therapeutic strategies. The exploration of these biomarkers may facilitate improved management and treatment options for patients, contributing to personalized care in keratoconus management.

29 July 2020 in Journal of Ophthalmic and Vision Research
Verified
Journal Article
Open access
PDF file
ARAlejandro Rodriguez-Garcia
Alejandro Rodriguez-Garcia
RARaul Alfaro-Rangel
Raul Alfaro-Rangel
ABAndres Bustamante-Arias
Andres Bustamante-Arias
JHJulio C. Hernandez-Camarena
Julio C. Hernandez-Camarena
Purpose: To describe and analyze the microstructural changes in herpetic stromal keratitis (HSK) observed in vivo by spectral-domain ocular coherence tomography (SD-OCT) at different stages of the disease. Methods: A prospective, cross-sectional, observational, and comparative SD-OCT analysis of corneas with active and inactive keratitis was performed, and the pathologic differences between the necrotizing and non-necrotizing forms of the disease were analyzed. Results: Fifty-three corneas belonging to 43 (81.1%) women and 10 (18.8%) men with a mean age of 41.0 years were included for analysis. Twenty-four (45.3%) eyes had active keratitis, and 29 (54.7%) had inactive keratitis; the majority (83.0%) had the non-necrotizing form. Most corneas (79.1%) with active keratitis showed stromal edema and inflammatory infiltrates. Almost half of the active lesions affected the visual axis, were found at mid-stromal depth, and had a medium density. By contrast, corneas with inactive keratitis were characterized by stromal scarring (89.6%), epithelial remodeling (72.4%), and stromal thinning (68.9%). In contrast to non-necrotizing corneas, those with necrotizing HSK showed severe stromal scarring, inflammatory infiltration, and thinning. Additionally, most necrotizing lesions (77.7%) affected the visual axis and had a higher density (P = 0.010). Conclusion: Active HSK is characterized by significant epithelial and stromal thickening and the inactive disease manifests epithelial remodeling at sites of stromal thinning due to scarring. Necrotizing keratitis is characterized by distorted corneal architecture, substantial stromal inflammatory infiltration, and thinning. In vivo SD-OCT analysis permitted a better understanding of the inflammatory and repair mechanisms occurring in this blinding corneal disease.

18 May 2023 in Current Eye Research
Verified
Journal Article
Closed access
ARAlejandro Rodriguez-Garcia
Alejandro Rodriguez-Garcia
RRRaul E. Ruiz-Lozano
Raul E. Ruiz-Lozano
ABAndres Bustamante-Arias
Andres Bustamante-Arias
JPJezreel Pantaleon-Garcia
Jezreel Pantaleon-Garcia
EHEverardo Hernandez-Quintela
Everardo Hernandez-Quintela
ANAlejandro Navas
Alejandro Navas
The Ocular Surface Disease Index (OSDI) is the most frequently used dry eye disease (DED) questionnaire, and the Symptom Assessment iN Dry Eye (SANDE) is the simplest and quickest to apply. We anal...